- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Mental Health Issues Overshadow Breast Cancer Survivorship
The Danish study, published in the Journal of Clinical Oncology, identified a 70% greater risk of severe depression in the first year after diagnosis.
Women who survive breast cancer face a higher risk of depression that can linger and require antidepressants, a new study finds.
Researchers in Copenhagen looked at data on nearly 2 million Danish women between 1998 and 2011, all of whom were initially free of cancer. During the study period, they found nearly 45,000 women were diagnosed with breast cancer.
The risk of having to check into a hospital for severe depression was 70 percent higher for the breast cancer patients in the first year after diagnosis than their cancer-free peers. The breast cancer patients were also three times more likely to use antidepressants during the first year after diagnosis.
Read the complete report on US News: http://bit.ly/1E5hGgJ
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
